Effects of serial levosimendan infusions on left ventricular performance and plasma biomarkers of myocardial injury and neurohormonal and immune activation in patients with advanced heart failure

Heart

Volumn 92, Issue 12, 2006, Pages 1768-1772

  Parissis, J T ^a,b   Adamopoulos, S ^b   Farmakis, D ^b   Filippatos, G ^b   Paraskevaidis, I ^b   Panou, F ^b   Iliodromitis, E ^b   Kremastinos, D Th ^b  

^a Aftocratoros   (Greece)

^b NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; INTERLEUKIN 6; LEVOSIMENDAN; NEUROHORMONE; PLACEBO; TROPONIN T;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLE; DOSE RESPONSE; DRUG EFFECT; DRUG INFUSION; ECHOCARDIOGRAPHY; FEMALE; GEOMETRY; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE PERFORMANCE; HEART MUSCLE INJURY; HUMAN; IMMUNE RESPONSE; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SYSTOLE; TREATMENT OUTCOME; TREATMENT RESPONSE;

AGED; CARDIOMYOPATHIES; CARDIOTONIC AGENTS; CYTOKINES; ELECTROCARDIOGRAPHY; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; HYDRAZONES; IMMUNITY, CELLULAR; INFUSIONS, INTRAVENOUS; MALE; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PYRIDAZINES; TREATMENT OUTCOME; TROPONIN T; VASODILATOR AGENTS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 33845228706     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.2006.079707     Document Type: Article

References (20)

1. Chatterjee K, Wolfe CL, De Marco T. Nonglycoside inotropes in congestive heart failure: are they beneficial or harmful? Cardiol Clin 1994;12:63-72.
2. 2-terminal kinase-dependent activation of the mitochondrial pathway. Circ Res 2003;92:136-8.
3. McBride B, White M. Levosimendan: implications for clinicians. J Clin Pharmacol 2003;43:1071-81.
4. Moiseyev VS, Poder P, Andrejevs N, et al. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN). Eur Heart J 2002;23:1422-32.
5. Follath F, Cleland JG, Just H, et al. Steering Committee and Investigators of the Levosimendan Infusion versus Dobutamine (LIDO) Study. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial, Lancet 2002;360:196-202.
6. Parissis J, Adamopoulos S, Antoniades C, et al. Effects of levosimendan on circulating pro-inflammatory cytokines and soluble apoptosis mediators in patients with decompensated advanced heart failure. Am J Cardiol 2004;93:1309-12.
7. Slawsky MT, Colucci WS, Goltlieb SS, et al. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Circulation 2000;102:2222-7.
8. Gould KL, Lipscomb K, Hamilton GW, et al. Relation of left ventricular shape, function and wall stress in man. Am J Cardiol 1974;34:627-34.
9. Francis G. Pathophysiology of chronic heat failure. Am J Med 2001;110:S37-46.
10. Mann DL. Mechanisms and models in heart failure: a combinatorial approach. Circulation 1999;100:999-1008.
11. Perna E, Macin S, Cimbaro C, et al. Ongoing myocardial injury in stable severe heart failure: value of cardiac troponin T monitoring for high-risk patient identification. Circulation 2004;110:2376-82.
12. Del Carlo C, Pereira-Barreto A, Cassaro-Strunz C, et al. Serial measure of cardiac troponin T levels for prediction of clinical events in decompensated heart failure. J Card Fail 2004;10:43-8.
13. Maeda K, Tsutamoto T, Wada A, et al. High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure. J Am Coll Cardiol 2000;36:1587-93.
14. Gabriel A, Martinsson A, Wretlind B, et al. IL-6 levels in acute and post myocardial infarction: their relation to CRP levels infarction size, left ventricular systolic function, and heart failure. Eur J Intern Med 2004;15:523-8.
15. Michaels AD, McKeown B, Kostal M, et al. Effects of intravenous levosimendan on human coronary vasomotor regulation, left ventricular wall stress, and myocardial oxygen uptake. Circulation 2005;111:1504-9.
16. Hasenfuss G, Pieske B, Castell M, et al. Influence of the novel inotropic agent levosimendan on isometric tension and calcium cycling in failing human myocardium. Circulation 1998;98:2141-7.
17. Nonas J, Papazoglou P, Tsagalou E, et al. Efficacy and safety of intermittent, long-term, concomitant dobutamine and levosimendan infusions in severe heart failure refractory to dobutamine alone. Am J Cardiol 2005;95:768-71.
18. Kyrzopoulos S, Adamopoulos S, Parissis J, et al. Levosimendan reduces plasma B-type natriuretic peptide and interleukin-6, and improves central hemodynamics in severe heart failure patients. Int J Cardiol 2005;99:409-13.
19. Avgeropoulou C, Andreadou I, Markantonis-Kyroudis S, et al. The Ca(2+)-sensitizer levosimendan improves oxidative damage, BNP and proinflammatory cytokine levels in patients with advanced decompensated heart failure in comparison to dobutamine. Eur J Heart Fail 2005;7:882-7.
20. Adamopoulos S, Parissis J, Kremastinos D. A glossary of circulating cytokines in chronic heart failure. Eur J Heart Fail 2001;3:517-26.